The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Multiple Myeloma Hub spotlight: Mechanism of action for CELMoDs in MM
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
Question 1 of 1
Which of the following is NOT an example of an immunomodulatory effect of CELMoDs in multiple myeloma?
A
B
C
D
⭐Multiple Myeloma Hub spotlight: Mechanism of action for CELMoDs in MM ⭐
Cereblon E3 ligase modulating drugs (CELMoDs) are next-generation immunomodulatory drugs (IMiDs) designed to enhance protein degradation and immune activation in multiple myeloma. By binding to cereblon, they promote targeted protein degradation, stimulate T cell and NK cell responses, and overcome IMiD resistance, improving anti-myeloma efficacy.
This educational resource is independently supported by Bristol Myers Squibb. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
